EMA Guidance: Orphan Medicinal Product Designation & Paediatric Applications
- Sharan Murugan
- 5 hours ago
- 2 min read
The European regulatory landscape continues to evolve with a strong focus on supporting innovation in rare diseases and ensuring safe, evidence-based development of medicines for children. The European Medicines Agency (EMA) has issued two key procedural guidelines:
together, establish a comprehensive regulatory framework that supports both rare disease innovation and paediatric medicine development.
This guidance outlines the regulatory process for obtaining orphan medicinal product designation in the European Union. It supports sponsors developing medicines for rare diseases by providing clarity on submission, evaluation, and decision-making processes.
The primary objective is to ensure that medicines intended for rare diseases meet key criteria, including addressing life-threatening or chronically debilitating conditions, demonstrating medical plausibility, and targeting diseases with low prevalence or insufficient commercial return without incentives.
Submission and Validation
Applications must include administrative data, a scientific document, proof of establishment in the European Economic Area, and supporting literature.
The EMA validates submissions to ensure completeness and compliance with regulatory requirements before initiating evaluation.
Evaluation Process
The COMP evaluates applications within a defined timeline, typically up to 90 days. The assessment focuses on scientific justification, prevalence data, and potential benefit over existing therapies.
Sponsors may be required to respond to questions or participate in oral explanations during the evaluation process.
Opinion and Decision
The COMP adopts an opinion, which is forwarded to the European Commission for a final decision. Sponsors may withdraw applications in case of negative outcomes or request an appeal if needed.
Guidance 2: Procedural advice on paediatric applications
This guidance provides detailed procedural advice for developing medicines intended for paediatric populations, ensuring that children have access to safe and effective treatments supported by high-quality evidence. The guidance aims to improve the availability of medicines for children by ensuring that they are ethically researched, appropriately authorised, and supported by robust scientific data.
General Principles
All paediatric applications must be submitted via the IRIS portal. Early planning and interaction with the EMA are critical to ensure alignment with regulatory expectations and avoid delays in development.
Paediatric Investigation Plans (PIPs)
A Paediatric Investigation Plan outlines how a medicine will be studied in children and must be submitted early in development, typically before completion of adult pharmacokinetic studies.
PIPs may include deferrals to delay studies in children until sufficient adult data are available.
Waivers and Modifications
Waivers may be granted when paediatric studies are not necessary or appropriate, while modifications allow updates to agreed PIPs when new scientific or operational challenges arise.
Compliance and Documentation
Applicants must demonstrate compliance with agreed PIPs before submitting marketing authorisation applications. This includes providing study results and supporting documentation for regulatory review.
Assessment and Decision
The PDCO evaluates applications through a structured process involving validation, assessment, and adoption of an opinion. Applicants may be required to respond to requests for supplementary information before a final decision is issued.
Also check out the Paediatric investigation plan (PIP) - Key elements form in this LINK
For complete official guidance, refer to:
Comments